-
1
-
-
33947280081
-
Dasatinib induces notable hematologic and cytogenetic responses in chronicphase chronic myeloid leukemia after failure of imatinib therapy
-
Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronicphase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.
-
(2007)
Blood
, vol.109
, pp. 2303-2309
-
-
Hochhaus, A.1
Kantarjian, H.M.2
Baccarani, M.3
Lipton, J.H.4
Apperley, J.F.5
Druker, B.J.6
-
2
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
Cortes, J.4
Shah, S.5
Ayala, M.6
-
3
-
-
70449467570
-
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily
-
Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily. Eur J Clin Invest 2009; 39: 1098-1109.
-
(2009)
Eur J Clin Invest
, vol.39
, pp. 1098-1109
-
-
Sillaber, C.1
Herrmann, H.2
Bennett, K.3
Rix, U.4
Baumgartner, C.5
Bohm, A.6
-
4
-
-
45449102076
-
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
-
Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127: 330-339.
-
(2008)
Clin Immunol
, vol.127
, pp. 330-339
-
-
Blake, S.1
Hughes, T.P.2
Mayrhofer, G.3
Lyons, A.B.4
-
5
-
-
52049085750
-
Dasatinib exerts an immunosuppressive effect on CD8\+ T cells specific for viral and leukemia antigens
-
Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J et al. Dasatinib exerts an immunosuppressive effect on CD8\+ T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36: 1297-1308.
-
(2008)
Exp Hematol
, vol.36
, pp. 1297-1308
-
-
Fei, F.1
Yu, Y.2
Schmitt, A.3
Rojewski, M.T.4
Chen, B.5
Greiner, J.6
-
6
-
-
58149181387
-
Dasatinib inhibits recombinant viral antigen-specific murine CD4\+ and CD8\+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
-
Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4\+ and CD8\+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37: 256-265.
-
(2009)
Exp Hematol
, vol.37
, pp. 256-265
-
-
Fraser, C.K.1
Blake, S.J.2
Diener, K.R.3
Lyons, A.B.4
Brown, M.P.5
Hughes, T.P.6
-
7
-
-
77950939774
-
Lck is a key target of imatinib and dasatinib in T-cell activation
-
Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010; 24: 896-900.
-
(2010)
Leukemia
, vol.24
, pp. 896-900
-
-
Lee, K.C.1
Ouwehand, I.2
Giannini, A.L.3
Thomas, N.S.4
Dibb, N.J.5
Bijlmakers, M.J.6
-
8
-
-
38949210227
-
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
-
Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.
-
(2008)
Blood
, vol.111
, pp. 1366-1377
-
-
Schade, A.E.1
Schieven, G.L.2
Townsend, R.3
Jankowska, A.M.4
Susulic, V.5
Zhang, R.6
-
9
-
-
42249088418
-
Profound inhibition of antigen-specific T-cell effector functions by dasatinib
-
Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14: 2484-2491.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2484-2491
-
-
Weichsel, R.1
Dix, C.2
Wooldridge, L.3
Clement, M.4
Fenton-May, A.5
Sewell, A.K.6
-
10
-
-
34247470836
-
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
-
Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 345-356
-
-
Weisberg, E.1
Manley, P.W.2
Cowan-Jacob, S.W.3
Hochhaus, A.4
Griffin, J.D.5
-
11
-
-
77958553932
-
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
-
Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85: 387-398.
-
(2010)
Eur J Haematol
, vol.85
, pp. 387-398
-
-
Rohon, P.1
Porkka, K.2
Mustjoki, S.3
-
12
-
-
79151480246
-
Primed tumor-reactive multifunctional CD62L\+ human CD8\+ T cells for immunotherapy
-
Wolfl M, Merker K, Morbach H, Van Gool SW, Eyrich M, Greenberg PD et al. Primed tumor-reactive multifunctional CD62L\+ human CD8\+ T cells for immunotherapy. Cancer Immunol Immunother 2011; 60: 173-186.
-
(2011)
Cancer Immunol Immunother
, vol.60
, pp. 173-186
-
-
Wolfl, M.1
Merker, K.2
Morbach, H.3
Van Gool, S.W.4
Eyrich, M.5
Greenberg, P.D.6
|